Phase II Study of AZD2171 (NSC 732208) in Patients With Malignant Mesothelioma.
Phase of Trial: Phase II
Latest Information Update: 30 Jul 2014
At a glance
- Drugs Cediranib (Primary)
- Indications Mesothelioma
- Focus Therapeutic Use
- 07 Jun 2017 Biomarkers information updated
- 23 Aug 2012 Status changed from completed to active, no longer recruiting as reported by ClinicalTrials.gov.
- 07 Mar 2012 Actual end date (Sep 2010) added as reported by ClinicalTrials.gov.